Johnson & Johnson (JNJ)vsVSee Health, Inc. (VSEE)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
VSEE
VSee Health, Inc.
$1.92
0.00%
HEALTHCARE · Cap: $929,550
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 628340% more annual revenue ($99.33B vs $15.81M). JNJ leads profitability with a 16.2% profit margin vs -62.6%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
VSEE
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Revenue surging 48.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Trading at 13.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -258.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : VSEE
The strongest argument for VSEE centers on Revenue Growth, Debt/Equity. Revenue growth of 48.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : VSEE
The primary concerns for VSEE are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while VSEE is a hypergrowth play — different risk/reward profiles.
VSEE carries more volatility with a beta of 0.40 — expect wider price swings.
VSEE is growing revenue faster at 48.0% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 41/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a leading innovator in the telehealth sector, providing secure video communication solutions tailored for healthcare providers and patients alike. Its comprehensive platform enhances care delivery through features such as remote patient monitoring, asynchronous messaging, and seamless EMR integration, thereby bolstering efficiency and quality across various medical disciplines. As the demand for virtual care surges in the evolving healthcare landscape, VSee's commitment to patient engagement and accessibility positions it strategically for significant growth. With a focus on innovation and client success, VSee Health is well-prepared to capitalize on the expanding digital healthcare market.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?